Table 2.
Changes Between Baseline and Week 96 in Human Immunodeficiency Virus Disease, Metabolic, and Mitochondrial Indices in Patients Receiving Abacavir-Lamivudine Versus Tenofovir DF–Emtricitabine (n = 39)
| Index | ABC/3TC | P (Within ABC/3TC) | TDF/FTC | P (Within TDF/FTC) | P (Between Groups) |
|---|---|---|---|---|---|
| CD4 cell count, cells/μL | 220 (142–307) | <.001 | 238 (116–357) | <.001 | .82 |
| Log10 HIV-1 RNA, copies/mL | −3.8 (−4.1 to −3.1) | <.001 | −3.8 (−4.6 to −3.2) | <.001 | .47 |
| BMI, kg/m2 | 1.2 (0.3–2.0) | .045 | 2.0 (0.2–4.9) | .02 | .12 |
| Limb fat, g | 906 (−349 to 1900) | .03 | 1479 (353–3032) | .008 | .30 |
| Visceral fat, cm2 | 14.2 (−7.5 to 30.7) | .06 | 16.1 (−4.6 to 33.6) | .21 | .93 |
| Fat mtDNA, copies/cell | −341 (−848 to 190) | .03 | −400 (−661 to −221) | <.001 | .57 |
| Complex I activity, OD × 103/µg | 2.6 (−4.4 to 11.1) | .67 | −12.45 (−24.7 to 2.9) | .003 | .03 |
| Complex IV activity, OD × 103/µg | −3.5 (−8.9 to 1.7) | .09 | −8.25 (−13.9 to −1.3) | <.001 | .13 |
The third drugs were combined in this comparison. Values represent median change (interquartile range).
Abbreviations: ABC/3TC, abacavir-lamivudine; BMI, body mass index; complex I, nicotinamide adenine dinucleotide (reduced) dehydrogenase; complex IV, cytochrome c oxidase; HIV-1, human immunodeficiency virus type 1; mtDNA, mitochondrial DNA levels; OD, optical density; TDF/FTC, tenofovir DF–emtricitabine.